

1 **Safety and immunogenicity of SW-BIC-213, a modified COVID-19**  
2 **Lipo-Polyplex mRNA vaccine, in Laotian healthy adults aged 18**  
3 **years and above: a Phase 1/2 trial**

4 Yujie Chen<sup>1, 8</sup>, Jingxin Li<sup>2, 8</sup>, Davone Duangdany<sup>3</sup>, Chanthala Phamisith<sup>4</sup>, Bo Yu<sup>1</sup>,  
5 Shengke Lan<sup>1</sup>, Lairun Jin<sup>2</sup>, Dawei Lv<sup>1</sup>, Yang Li<sup>1</sup>, Bin Luo<sup>1</sup>, Peng Han<sup>1</sup>, Jinyan Wu<sup>1</sup>,  
6 Yuzhu Wang<sup>1</sup>, Congcong Xu<sup>1</sup>, Mingyun Shen<sup>1</sup>, Fanfan Zhao<sup>1</sup>, Peipei Liu<sup>5</sup>, Rongjuan  
7 Pei<sup>6</sup>, Haifa Shen<sup>1</sup>, Wuxiang Guan<sup>6,9</sup>, Hangwen Li<sup>1, 9</sup>, Mayfong Mayxay<sup>7, 9</sup>

8  
9 **Affiliations:**

- 10 1. Stemirna Therapeutics, Shanghai, China  
11 2. Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China  
12 3. Food and Drug Department, Ministry of Health, Vientiane, Laos  
13 4. Savannakhet Province Hospital, Savannakhet, Laos  
14 5. Chinese center for disease control and prevention, China  
15 6. Wuhan Institute of Virology, Wuhan, China  
16 7. Institute of Research and Education Development, University of Health Sciences,  
17 Vientiane, Lao People's Democratic Republic  
18 8. Joint first authors; contributed equally  
19 9. Joint senior authors; contributed equally

20 **Correspondence to:**

21 Wuxiang Guan, [guanwx@wh.iov.cn](mailto:guanwx@wh.iov.cn)  
22 Hangwen Li, [lihangwen@stemirna.com](mailto:lihangwen@stemirna.com)  
23 Mayfong Mayxay, [mayfong@tropmedres.ac](mailto:mayfong@tropmedres.ac)

24 **Lead contact:**

25 Hangwen Li, [lihangwen@stemirna.com](mailto:lihangwen@stemirna.com)  
26  
27  
28

29

## ABSTRACT

30 **Background** The mRNA vaccine against SARS-CoV-2 has demonstrated remarkable efficacy in  
31 protecting against coronavirus disease 2019 (COVID-19), including providing high protection  
32 against severe disease during the emergence of variant waves. In this study, we aimed to  
33 investigate the safety and immunogenicity of a 2-dose regimen of the LPP-based mRNA vaccine,  
34 SW-BIC-213, in Laos.

35 **Methods** For this phase 1/2 clinical trial, we recruited healthy adults aged 18-60 years (phase 1)  
36 or  $\geq 18$  years (phase 2) from Mahosot Hospital (Vientiane) and Champhone District Hospital  
37 (Savannakhet). Participants with SARS-CoV-2 infection, previous COVID-19 vaccination, known  
38 allergies to any vaccine component, or pregnancy were excluded. In the phase 1 trial, 41 eligible  
39 participants were sequentially assigned to either the 25  $\mu\text{g}$  dose group (25  $\mu\text{g}$ ) or the 45  $\mu\text{g}$  dose  
40 group (45  $\mu\text{g}$ ) in accordance with their enrollment order, with 21 participants in 45  $\mu\text{g}$  dose group  
41 and 20 participants in 25  $\mu\text{g}$  dose group. In the phase 2 trial, 480 participants were randomly  
42 allocated (2:2:1 ratio) to either the 25  $\mu\text{g}$  dose group, 45  $\mu\text{g}$  dose group, or placebo group.

43 The primary endpoints for the phase 1 trial were the incidence of local/systemic solicited adverse  
44 reactions/events (0-6 days after each vaccination dose), unsolicited adverse events (0-21 days and  
45 0-28 days after the first and second dose of immunization, respectively), and serious adverse events  
46 from the first dose of vaccination to 28 days after completing the full course of immunization. In  
47 the phase 2 trial, the primary endpoints were the seroconversion rate and geometric mean titer  
48 (GMT) of SARS-CoV-2 S-protein specific IgG antibodies and neutralizing antibodies 14 days  
49 after the second dose in participants. As for neutralizing antibodies, we detected pseudo-virus  
50 neutralizing antibody against wild type (WT), Delta, BA.1 and BA.2. We also detected live viral  
51 neutralizing antibody against WT strain 14 days after the second dose. Furthermore, the safety  
52 endpoints were also measured during the trial.

53 This seamless phase 1/2 trial was registered with ClinicalTrials.gov under the identifier  
54 NCT05144139.

55 **Results** Between December 3, 2021, and March 31, 2022, a total of 41 participants were recruited  
56 in the phase 1 trial, while the phase 2 trial enrolled 480 participants from January 20 to July 6,  
57 2022. In the phase 1 trial, a total of 32 subjects (80.0%) reported 103 cases of adverse reactions.  
58 All adverse reactions were limited to Grade 1-2. In the phase 2 trial, a total of 479 subjects, 372

59 subjects (77.7%) reported 929 cases of adverse reactions. All adverse reactions in severity of Grade  
60 3 were manifested as fever (3.4%, 2.1% and 2.9% in 45 µg dose, 25 µg dose and placebo group  
61 respectively, only observed in adults), except which all other reactions were limited to Grade 1-2.  
62 All adverse reactions noted during the study were tolerable, predominantly transient, and resolved  
63 spontaneously. No serious adverse events (SAEs) related to vaccination were observed.  
64 In Phase 2 study, SW-BIC-213 could elicit a high level of seroconversion rate of pseudo-virus  
65 neutralizing antibody against WT (100.0% in 25 µg dose group, 99.3% in 45 µg dose group), Delta  
66 (99.2% in 25 µg dose group, 98.0% in 45 µg dose group), Omicron BA.1 (84.1% in 25 µg dose  
67 group, 84.7% in 45 µg dose group) and Omicron BA.2 (96.0% in 25 µg dose group, 88.8% in 45  
68 µg dose group) at 14 days after the second dose. The pseudo-virus neutralizing antibody titer  
69 against WT, Delta, BA.1 and BA.2 was all significant higher ( $P<0.0001$ ) in both 45 µg dose group  
70 (1175.02, 620.62, 72.39 and 172.80) and 25 µg dose group (885.80, 579.40, 47.24 and 101.96)  
71 compared with the placebo group (9.67, 10.66, 13.99 and 29.53) at 14 days after the second dose.  
72 As for live viral neutralizing antibodies against WT strain, the seroconversion rate could reach  
73 more than 94% at 14 days after second dose. The neutralizing antibody titer against WT strain was  
74 significantly higher ( $P<0.0001$ ) in both 45 µg dose group (315.00) and 25 µg dose group (323.18)  
75 compared with the placebo group (8.51) at 14 days after second dose.

76 **Conclusion:** COVID-19 mRNA vaccine SW-BIC-213 manifests a favorable safety profile and is  
77 highly immunogenic in eligible subjects aged  $\geq 18$  years.

78 **Keywords:** SARS-CoV-2, mRNA vaccine, SW-BIC-213, LPP, Clinical trial, Laos

79

## 80 INTRODUCTION

81 Since the emergence of COVID-19, it has had a huge impact on the whole world<sup>1</sup>. According to  
82 statistics from the World Health Organization (WHO), there has been over 767 million confirmed  
83 cases of COVID-19, including 6.9 million deaths as of June 2023<sup>2</sup>. One of the best ways to prevent  
84 and slow down the transmission is vaccination<sup>3</sup>.

85 In response to the COVID-19 outbreak caused by the SARS-CoV-2 virus, numerous of vaccines  
86 development programs have been launched. As of March 2023, the World Health Organization's  
87 vaccine tracker reported a total of 382 vaccine candidates under development<sup>4</sup>. These candidates  
88 utilize various platforms, including live attenuated vaccines, recombinant protein vaccines, vector  
89 vaccines (replication-incompetent vector vaccines, replication-competent vector vaccines, and  
90 inactivated virus vector vaccines), DNA vaccines and RNA vaccines<sup>5-10</sup>. Among these platforms,  
91 mRNA vaccines have demonstrated the highest protective efficacy<sup>5-7</sup>. Notably, BNT162b2 and  
92 mRNA-1273 are representative mRNA vaccines against SARS-CoV-2. The BNT162b2 vaccine,  
93 administered as a two-dose regimen (30 µg per dose, with a 21-day interval), has shown a safety  
94 profile and 95% efficacy against COVID-19<sup>11</sup>. Similarly, the mRNA-1273 vaccine exhibited 94.1%  
95 efficacy in preventing COVID-19 illness, including severe disease<sup>12</sup>. These vaccines have made  
96 significant contributions in controlling the COVID-19 pandemic and have demonstrated the  
97 feasibility of mRNA vaccine technology.

98 SW-BIC-213 is an investigational mRNA that encodes a modified full-length spike protein of WT  
99 SARS-CoV-2, incorporating mutations such as 2P mutation, furin mutation, and D614G  
100 mutation<sup>13</sup>. It is based on Lipo-Polyplex (LPP) platform<sup>14</sup>. In this study, we present the clinical  
101 trial data from a Phase 1/2 trial among healthy volunteers in Laos (Lao PDR) to assess the safety  
102 and immunogenicity of the LPP-based mRNA vaccine against COVID-19.

103

104

105

106

## 107 **METHODS**

### 108 **Study design and participants**

109 We conducted a seamless Phase 1/2 study in Laos to evaluate the safety and immunogenicity of  
110 the COVID-19 mRNA vaccine. The Phase 1 trial employed an open-label, single-arm, dosage-  
111 escalating design and included healthy individuals aged 18-60 years. The Phase 2 trial utilized a  
112 randomized, double-blind, placebo-controlled design and enrolled healthy individuals aged 18  
113 years and above.

114 During the screening visit, participants underwent a medical history review and physical  
115 examination to ensure overall good health. Both male and female participants of childbearing age  
116 agreed to use contraception throughout the trial, and pregnant individuals were excluded.  
117 Exclusion criteria included a history of SARS/MERS or SARS-CoV-2 infection, experiencing  
118 common clinical features of COVID-19 within 14 days prior to enrollment, allergies to vaccine  
119 components, history of seizures or mental illness, acute or chronic diseases in the acute phase,  
120 congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, or other  
121 autoimmune diseases, receipt of blood products within the past 3 months, receipt of other study  
122 drugs within the past 6 months, or receipt of any COVID-19 vaccine. The exclusion of  
123 SARS/MERS or SARS-CoV-2 infection was achieved by asking about infection history and  
124 detecting IgG level (2019-nCoV IgG/IgM Detection Kit, Vazyme). Prior to participation, all  
125 individuals received comprehensive information about the trial procedures and potential risks and  
126 provided their written informed consent.

127 The trial received approval from the Ethics Committee and Food & Drug Department of the  
128 Ministry of Health, Lao PDR (7745). The protocol and each amendment underwent review by the  
129 Independent Ethics Committee of the Lao People's Democratic Republic Ministry of Health  
130 National Ethics Committee for Health Research. The study adhered to the principles outlined in  
131 the Declaration of Helsinki and Good Clinical Practice Guidelines. Safety assessment, including  
132 the necessity of study suspension or termination, was conducted by an independent Data Safety  
133 Monitoring Board (DSMB).

134 The trial was registered with the identifier NCT05144139 on ClinicalTrials.gov.

135

136

137

### 138 **Randomization and blinding**

139 In the Phase 1 trial (open-label), eligible participants were assigned in a 1:1 ratio to receive either  
140 a 25 µg dose or a 45 µg dose of SW-BIC-213 based on their enrollment sequence. The trial was  
141 carried out step by step from the 25 µg dose group to the 45 µg dose group, the 45 µg dose group  
142 was enrolled only when the preliminary 7-day safety assessment of the 25 µg dose group was  
143 favorable. The Phase 2 trial (blinded) included two age cohorts: the adult group ( $\geq 18$  to  $\leq 60$  years  
144 old) and the seniors group ( $> 60$  years old), with a ratio of 3:1. Within each age group, participants  
145 were randomized in a 1:1:1 ratio to receive either a 25 µg dose of SW-BIC-213, a 45 µg dose of  
146 SW-BIC-213, or a placebo. The randomization of participants into vaccine groups was performed  
147 using an interactive response technology (IRT) system. The blocked randomization list was  
148 generated by an independent statistician utilizing the SAS system (version 9.4 or later). The staff  
149 responsible for vaccine receiving, storing, dispensing, and preparation, who were unblinded, had  
150 no further involvement in the trial and were strictly prohibited from disclosing any information  
151 that could compromise blinding. Throughout the trial, all other investigators, participants,  
152 laboratory staff, and the sponsor remained blinded.

### 153 **Procedures**

154 The SW-BIC-213 vaccine was composed of an mRNA encoding full-length spike glycoprotein of  
155 the Wuhan-HU-1 isolate of SARS-CoV-2. This mRNA included artificial mutations, such as the  
156 K986P/V987P (pre-fusion structure) mutation, the 682-QSAQ-685 mutation (substitution of Furin  
157 cleavage site), and the D614G mutation. This vaccine was formulated with lipo-polyplex and was  
158 developed and manufactured by StemiRNA Therapeutics Co., Ltd, in Shanghai, China, in  
159 accordance with good manufacturing practice guidelines. The vaccine was supplied as a buffered-  
160 liquid solution in vials, with each vial containing 50 µg of the vaccine in 0.5 mL. It was stored at  
161 temperatures ranging from  $-25^{\circ}\text{C}$  to  $-15^{\circ}\text{C}$  until use. The placebo consisted of a commercial, pre-  
162 packaged preservative-free saline solution containing 0.9% NaCl.

163 Each participant received two doses of the SW-BIC-213 vaccine candidate, each dose was 25 µg  
164 or 45 µg or placebo. The vaccinations were administered in the upper arm deltoid muscle, with an  
165 interval of 21 days between each dose. Following each dose, participants were observed on-site  
166 for 30 minutes, during which any adverse reactions were recorded by the investigators. Participants  
167 documented their body temperature and any adverse events on daily cards during the first 7 days

168 after each vaccination. Participants reported any adverse events occurring within 7-21 and 7-28  
169 days after the first and second vaccination, respectively, using contact cards. Any serious adverse  
170 events or pregnancies that developed from the first vaccination until the end of the study were  
171 monitored, and follow-up was ongoing. In Phase 1 only, participants underwent blood and urine  
172 sample collection before and 4 days after each dose for hematology and chemistry laboratory tests  
173 to assess any toxicity following vaccination. The enrollment of each dosage group in the Phase 2  
174 study was carried out only if the corresponding dosage group in the Phase 1 study demonstrated a  
175 favorable safety profile.

176 Solicited local adverse events at the injection site within 7 days after vaccination included pain,  
177 pruritus, induration, swelling, redness. Solicited systemic adverse events within 7 days after  
178 vaccination included fever, fatigue, headache, myalgia, chills, arthralgia, nausea, swollen lymph  
179 nodes (lymphadenopathy), diarrhea, vomiting and acute allergic reaction. Unsolicited adverse  
180 events occurring within 0-21 days and 0-28 days after the first and second dose respectively were  
181 collected. Unsolicited adverse events were adverse events that were not included in the protocol-  
182 defined solicited adverse reactions. The severity of adverse events were assessed according to  
183 Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events  
184 (Version 2.1)<sup>15</sup>. The severity of abnormality in vital sign and laboratory test were primarily  
185 evaluated using the Guidelines for Adverse Event Classification Standards for Clinical Trials of  
186 Preventive Vaccines issued by NMPA (National Medical Products Administration) in 2019<sup>16</sup>, and  
187 further complemented by Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers  
188 Enrolled in Preventive Vaccine Clinical Trials issued by the FDA in 2007<sup>17</sup>. The causal association  
189 between adverse events and vaccination was final determined by experienced doctors based on  
190 actual situation.

191 Blood samples were collected from participants before each dose of vaccination and 14, 90, and  
192 180 days after the second dose. These samples were used to evaluate antibody responses,  
193 specifically Spike/RBD-specific IgG antibodies and neutralizing antibodies against SARS-CoV-2.  
194 The titer of total anti-SARS-CoV-2 spike IgG antibodies were determined using an indirect ELISA  
195 assay. ELISA plates were coated with recombinant SARS-CoV-2 spike protein. Plates were  
196 washed with PBS-T (phosphate buffered saline (PBS) with 0.05% Tween-20) and blocked with 2%  
197 goat serum in PBS-T. Serially diluted standard antibody to SARS-CoV-2 spike protein and heat-  
198 inactivated human serum samples at a certain dilution were added into wells in duplicate. The



199 bound antigen–antibody complex was detected using a rabbit anti-human IgG horseradish  
200 peroxidase (HRP) conjugate, and color development occurred upon the addition of 3,3' 5,5'-  
201 tetramethylbenzidine (TMB) chromogenic substrate. The absorbance was measured using a  
202 microplate reader at 450/630 nm. The titer of IgG in serum samples was quantified using a  
203 calibration curve and expressed as RU/mL, which was later converted to WHO International  
204 Standard titer (NIBSC CODE: 20/136) as binding antibody units per mL (BAU/mL). Additionally,  
205 RBD-specific IgG antibodies were detected using a commercial kit from Vazyme (Nanjing, China)  
206 using a similar method. The detection range of binding antibody is 20-800 BAU/ml.

207 The neutralizing antibody titer was determined by a vesicular stomatitis virus (VSV)-based  
208 pseudo-virus neutralization assay using commercial kits (Zhongxingrongchuang biotech, Beijing,  
209 China). The SARS-CoV-2 pseudo-viruses express full-length spike proteins (Prototype/ Delta/  
210 Omicron BA.1/ Omicron BA.2) and containing a firefly luciferase reporter gene for quantitative  
211 measurements of infection by relative light units (RLU). Briefly, SARS-CoV-2 pseudo-virus was  
212 preincubated with three-fold serially diluted heat-inactivated human serum samples for 1 hour at  
213 37 °C. The medium was also mixed with pseudo-virus as virus control. Then, Vero cells were  
214 inoculated with the respective mixtures in 96-well plates. After incubation for 24h at 37 °C, the  
215 cells were lysed, and luciferase activity was measured using a commercial substrate according to  
216 the manufacturer's protocol (Vazyme, Nanjing, China). Luminescence intensity was measured  
217 using a microplate reader. The neutralization titer was defined as the reciprocal serum dilution  
218 necessary for 50% inhibition of luciferase activity compared with the virus control wells,  
219 calculated using the Reed-Muench method. The cut-off value of WT, Delta, BA.1, BA.2 pseudo-  
220 virus neutralizing antibody is 8, 8, 5, 6, respectively.

221 Neutralizing antibody titers were determined using a micro-neutralization assay conducted in a  
222 biosafety level III laboratory. Serum samples were serially diluted and then incubated at 37°C for  
223 one hour with 100 TCID<sub>50</sub> doses of the live SARS-CoV-2 WT strain. The serum-virus mixture  
224 was then added to Vero cells and incubated for four days. Cytopathic effects (CPE) were observed  
225 under electron microscopy, and the serum dilution factor that resulted in 50% CPE was recorded  
226 as the neutralizing antibody titer. The cut-off value of neutralizing antibody in phase 1 trial is 2.  
227 The detection range of neutralizing antibody is 10-4426 in phase 2 trial.

228  
229



## 230 **Outcomes**

231 In the phase 1 trial, the primary outcome focused on the safety of COVID-19 mRNA vaccine in  
232 healthy people aged 18-60 years. The secondary outcome assessed the humoral immunogenicity  
233 and long-term safety for six months. In the phase 2 trial, the primary outcome aimed to evaluate  
234 the humoral immunogenicity and safety in healthy people aged 18 years and above. The secondary  
235 outcome examined the long-term safety and persistence of humoral immunity for six months.

236 Safety outcomes included the incidence of local/systemic solicited adverse reactions/events (0-6  
237 days after each vaccination dose), unsolicited adverse events (0-21 days and 0-28 days after the  
238 first and second dose of immunization, respectively), and serious adverse events from the first dose  
239 of vaccination to 28 days after completing the full course of immunization.

240 Outcomes for immunogenicity included seroconversion rate and GMT of SARS-COV-2 spike  
241 protein specific IgG antibody and neutralizing antibody (Pseudo-virus neutralizing antibody  
242 targeting WT, Delta, Omicron BA.1 and Omicron BA.2 14 days after the second dose; live viral  
243 neutralizing antibody against WT strain) 14 days after the second dose. In addition, RBD specific  
244 IgG antibody was investigated in phase 1 trial as an exploratory endpoint.

## 245 **Statistical analysis**

246 The safety analysis included all participants who received at least one dose of the investigational  
247 vaccine. Immunogenicity analyses were primarily based on the per protocol set (PPS) and  
248 supplemented by the full analysis set (FAS) at various time points, as defined in the study protocol.

249 The full analysis set comprised all subjects who received at least one dose of vaccination and had  
250 valid pre-vaccination antibody results. Moreover, the Per protocol set referred to participants who  
251 were enrolled, following the inclusion and exclusion criteria, completed the vaccination course as  
252 protocol defined in the protocol, and had valid pre-vaccination and post-vaccination  
253 immunogenicity data. Safety endpoints were presented as percentage of participants experiencing  
254 adverse events or serious adverse events during the observation period. To compare the differences  
255 in proportions across the groups, Fisher's exact test was used. Immunological analysis for IgG and  
256 neutralizing antibodies included seroconversion rates and GMT at specified time points. We  
257 calculated 95% confidence intervals using the Clopper-Pearson method. Chi-square test/Fisher's  
258 exact test was used to compare differences in seroconversion rates among the groups. We  
259 performed a t-test after log-transformation to compare differences in GMT between the groups.  
260 All statistical analyses were conducted using SAS version 9.4.

261 In phase 1 trial, the probability to observe a particular adverse event with an incidence of 8% at  
262 least once in 20 participants in each dose group was 81.1%. The actual enrolled sample size was  
263 41. For phase 2, the sample size calculation was based on the assumption that the seroconversion  
264 rate of vaccine and placebo groups be 80% and 10%, respectively, and the test level would be a  
265 unilateral  $\alpha=0.025$ . We calculated that, with a sample size of 144 subjects in each vaccine group  
266 and 36 subjects in each placebo group for adults and 48 subjects in each vaccine group and 12  
267 subjects in each placebo group for seniors, the difference between the vaccine and placebo could  
268 be estimated with at least 99% confidence including the consideration of 33% dropout rate. The  
269 actual enrolled sample size was 480.

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

## 292 **RESULTS**

### 293 **Patient characteristics**

294 Between December 3, 2021, and March 31, 2022, a total of 94 individuals underwent recruitment  
295 and screening for Phase 1 trial in Vientiane and Savannakhet, Laos (Fig. 1A). After excluding 53  
296 individuals, 41 eligible participants were assigned to two groups, receiving either the 25 µg dose  
297 (n=20) or the 45 µg dose (n=21) of the vaccine. Among them, 40 participants (20 in the 45 µg dose  
298 group and 20 in the 25 µg dose group) received their first vaccination, and 39 participants (19 in  
299 the 45 µg dose group and 20 in the 25 µg dose group) completed the two-dose immunization. The  
300 mean age in the 25 µg dose group was 31.3 years, and in the 45 µg dose group was 30.2 years,  
301 with a balanced age distribution between the two vaccination groups (Table 1).

302 Between January 20, 2022, and July 6, 2022, a total of 863 individuals underwent recruitment and  
303 screening for Phase 2 trial in Vientiane and Savannakhet, Laos (Fig. 1B). After excluding 383  
304 individuals, 480 eligible participants were randomly assigned to three groups, receiving either the  
305 25 µg dose (n=192) or the 45 µg dose (n=192) of the vaccine, or placebo (n=96). The mean ages  
306 for the placebo group, 25 µg dose group, and 45 µg dose group were 46.3 years, 47.5 years, and  
307 47.3 years, respectively, with a balanced age distribution among the vaccination groups (Table 1).  
308 In the Phase 2 study, a total of 479 eligible subjects received their first vaccination on the deltoid  
309 muscle, with the investigational vaccine dosage of 25 µg or 45 µg, or placebo. Of them, 376  
310 received the second vaccination using the same immune route and dosage as the first vaccination.

### 311 **Safety**

312 The Phase 1 study revealed common adverse reactions, including systemic diseases and various  
313 local reactions at the site of administration, such as pain (80.0% in 45 µg dose group and 50.0% in  
314 25 µg dose group), fever (25.0% in 45 µg dose group and 30.0% in 25 µg dose group), fatigue  
315 (30.0% in 45 µg dose group and 15.0% in 25 µg dose group), swelling (10.0% in 45 µg dose group  
316 and 5.0% in 25 µg dose group), and headache (35.0% in 45 µg dose group and 5.0% in 25 µg dose  
317 group). These reactions were limited to grade 1 or 2, with only the occurrence of headache showing  
318 a significant difference between the 25 µg dose group and 45 µg dose group (P=0.0436) (Fig. 2A).  
319 Nonetheless, all adverse symptoms resolved, mostly spontaneously, and their severity remained  
320 limited to Grade 1-2. No grade  $\geq 3$  adverse reactions were reported until the data cutoff date.

321 Similarly, in the Phase 2 study, common adverse reactions were pain (72.4%, 70.8% and 35.7%  
322 for 45 µg dose, 25 µg dose and placebo group, respectively, in adults; 93.8%, 72.9% and 16.7%  
323 for 45 µg dose, 25 µg dose and placebo group, respectively, in seniors) at the injection site, fever  
324 (37.9%, 36.8% and 35.7% in adults; 33.3%, 33.3% and 12.5% in seniors), fatigue (3.4%, 16.0%  
325 and 5.7% in adults; 14.6%, 4.2% and 4.2% in seniors), headache (9.7%, 16.7% and 21.4% in adults;  
326 12.5%, 10.4% and 16.7% in seniors), with primarily grade 1 or 2 intensity. Grade  $\geq 3$  adverse  
327 reaction was only observed in fever and in adults, the incidence was merely 3.4%, 2.1% and 2.9%  
328 in 45 µg dose, 25 µg dose and placebo group respectively. Notably, in the adults group and seniors  
329 group, the incidence of pain at the injection site was significantly higher ( $P < 0.0001$ ) in the vaccine  
330 group (72.4% and 93.8% for 45 µg dose group, 70.8% and 72.9% for 25 µg dose group) compared  
331 to the placebo group (35.7% and 16.7%). Moreover, in the adult group, the incidence of fatigue  
332 was significantly higher in the 25 µg dose group compared to the placebo group ( $P = 0.0005$ ) (Fig.  
333 2B). Other adverse effects did not show statistically significant differences between the 45 µg dose  
334 group and 25 µg dose group. As with Phase 1, all adverse symptoms resolved, with most of them  
335 being transient and self-recovering.

336 In conclusion, the COVID-19 mRNA vaccine, SW-BIC-213, demonstrated a favorable safety  
337 profile and was well tolerated by eligible subjects aged  $\geq 18$  years, regardless of the dose and study  
338 phase. Local reactions were more prevalent than systemic reactions among all participants. The  
339 adverse reactions observed during the trial were generally tolerable, transient, and self-resolving.  
340 All grade 3 adverse reactions were characterized as grade 3 fever and were successfully treated.

### 341 **Immunogenicity assessments**

342 In the Phase 1 trial, we assessed antibody responses by measuring participants' serological spike-  
343 binding IgG titer using ELISA. Comparing data from each vaccination, the post-vaccination GMT  
344 in both groups showed an ascending trend from baseline to 21 days after the first dose, and further  
345 increased by 14 days after the second dose (Fig. 3A). In 45 µg dose group, GMT increased from  
346 12.82 BAU/ml at baseline, through 306.70 after receiving the first dose, to 1853.40 BAU/ml after  
347 receiving the second dose. In 25 µg dose group, GMT increased from 11.46 BAU/ml at baseline,  
348 through 275.71 BAU/ml after receiving the first dose, to 924.17 BAU/ml after receiving the second  
349 dose (Fig. 3A). Although the GMT of the 45 µg dose group was higher than that of the 25 µg dose  
350 group 14 days after the second dose, no statistically significant difference was observed ( $P = 0.0531$ )  
351 (Fig. 3A). The seroconversion rate of S-protein antibody after the first vaccination was 100.0% in

352 both the 45 µg dose group and 25 µg dose group, while after the second vaccination, it was 100.0%  
353 in the 45 µg dose group and 94.7% in the 25 µg dose group (Fig. 3B). No significant differences  
354 were found between the groups ( $P = 1.0000$ ). Additionally, both the 45 µg dose group and 25 µg  
355 dose group exhibited 100.0% seroconversion rates for S-protein specific antibody at both 90 days  
356 and 180 days after full immunization (Fig. 3B).

357 Given the importance of the RBD domain of the S protein for viral entry, antibodies targeting this  
358 domain of SARS-CoV-2 were expected to be neutralizing and potentially protective. Therefore,  
359 we also measured RBD-binding IgG antibodies using ELISA. Similar to the spike-binding IgG  
360 antibodies, GMT post-vaccination in both groups showed an ascending trend from baseline  
361 through 21 days after the first dose to 14 days after the second dose (Supplementary Fig. 1A). In  
362 45 µg dose group, GMT increased from 12.34 BAU/ml at baseline, through 138.06 BAU/ml after  
363 receiving the first dose, to 1988.90 BAU/ml after receiving the second dose. In 25 µg dose group,  
364 GMT increased from 10.46 BAU/ml, through 154.79 BAU/ml after receiving the first dose, to  
365 1127.61 BAU/ml after receiving the second dose (Supplementary Fig. 1A). After completing full  
366 immunization, the GMT in the 45 µg dose group was higher than that in the 25 µg dose group, but  
367 no significant differences were observed between the groups ( $P = 1.0000$ ). The seroconversion  
368 rate of S-protein antibody after the first vaccination was 94.7% in the 45 µg dose group and 100.0%  
369 in the 25 µg dose group, while after the second vaccination, it was 100.0% in the 45 µg dose group  
370 and 94.7% in the 25 µg dose group (Supplementary Fig. 1B). Seroconversion rates of RBD  
371 combining antibody in both the 45 µg dose group and 25 µg dose group remained at 100.0% at  
372 both 90 days and 180 days after full immunization (Supplementary Fig. 1B), with no significant  
373 differences between the groups ( $P = 1.0000$ ).

374 In the Phase 2 trial, adults and seniors in the 45 µg dose group and 25 µg dose group showed an  
375 increasing trend in GMT of S-protein specific antibody from baseline through 21 days after the  
376 first dose to 14 days after the second dose (Fig. 3C). Among younger subjects, the GMT of S-  
377 protein specific antibody was significantly higher in the experimental group compared to the  
378 placebo group after each dose, especially detected at 14 days after the second dose (2051.94  
379 BAU/mL, 1853.02 BAU/mL and 20.52 BAU/mL in 45 µg dose group, 25 µg dose group and  
380 placebo group, respectively,  $P < 0.0001$ ) (Fig. 3C). However, no significant difference ( $P = 0.1307$ )  
381 was observed between the 45 µg dose group and 25 µg dose group 14 days after the second dose  
382 (Fig. 3C). Among seniors group, the GMT of S-protein specific antibody was significantly higher

383 in the experimental group compared to the placebo group after each dose, detected at 14 days after  
384 the second dose (3455.81 BAU/mL, 1471.12 BAU/mL and 16.26 BAU/mL in 45 µg dose group,  
385 25 µg dose group and placebo group, respectively,  $P < 0.0001$ ), with the 45 µg dose group  
386 demonstrating notably higher GMT compared to the 25 µg dose group ( $P < 0.0001$ ) (Fig. 3C).  
387 Among younger subjects who received the experimental vaccine, the first dose of vaccination (98.1%  
388 for 45 µg dose group, 100% for 25 µg dose group) induced a comparable seroconversion rate to  
389 that after the second dose (99.0% in 45 µg dose group, 100% in 25 µg dose group) (Fig. 3D). The  
390 seroconversion rate induced by the experimental vaccine was significantly higher than that elicited  
391 by the placebo (19.4%) at 14 days after the second dose ( $P < 0.0001$ ), but there was no significant  
392 difference ( $P = 1.0000$ ) between the 45 µg dose group (99.3%) and 25 µg dose group (100.0%).  
393 When comparing between age cohorts, the seroconversion rates after full immunization in both  
394 cohorts were generally balanced, with both reaching higher than or equal to 99.0%. At 90 days and  
395 180 days after full immunization, the seroconversion rates of S-protein specific antibody in both  
396 the 45 µg dose group and 25 µg dose group in each age cohort remained at a level of  $\geq 97\%$  (Fig.  
397 3D).

398 The serum samples of participants were also assessed for pseudo-virus neutralizing titers against  
399 SARS-CoV-2 prototype strain and three variants of concern (VOC) strains (Delta, Omicron BA.1,  
400 and Omicron BA.2). In the Phase 1 trial, the GMT of pseudo-virus neutralizing antibody against  
401 WT and Delta strain reached 990.50 and 642.08 in 45 µg dose group at 14 days after the second  
402 dose, 507.17 and 352.98 in 25 µg dose group respectively (Fig. 4A, B). As for BA.1 and BA.2, the  
403 GMT at 14 days after the second dose was relatively lower, which was 35.27 and 55.88 in 45 µg  
404 dose group, 25.12 and 36.27 in 25 µg dose group (Fig. 4C, D). After receiving two doses of  
405 vaccination, the GMTs for all strains in the 45 µg dose group were consistently higher than that in  
406 the 25 µg dose group, but there was no significant difference ( $P > 0.05$ ). At 14 days after full  
407 immunization, in the 45 µg dose group, the seroconversion rate of neutralizing antibodies against  
408 WT, Delta, BA.1, and BA.2 were 100.0%, 100.0%, 82.4%, and 82.4%, respectively  
409 (Supplementary Fig. 2A, B, C, D). In the 25 µg dose group, these rates were 94.7%, 94.7%, 84.2%,  
410 and 47.4%, respectively (Supplementary Fig. 2 A, B, C, D). Except for BA.2 ( $P = 0.0291$ ),  
411 seroconversion rates for other strains were balanced between groups ( $P > 0.05$ ) (Supplementary Fig.  
412 2A, B, C, D). The GMT of neutralizing antibodies against each strain in each group declined from  
413 90 days to 180 days after the second dose, except for neutralizing antibody against Omicron BA.1



414 in the 25 µg dose group, which slightly rose during this period (Fig. 4A, B, C, D). This trend was  
415 in line with the seroconversion rate analysis, suggesting that it might be attributed to the activation  
416 of immune memory cells by exposure to the pathogen or the hybrid immunity induced by infection.  
417 In the Phase 2 trial, the vaccine group showed a significant increase in pseudo-virus neutralizing  
418 antibodies against WT, Delta, BA.1, and BA.2 compared to the placebo group (Fig. 4E, F, G, H).  
419 At 14 days after the second dose, the GMTs of antibodies against each strain in the 45 µg dose  
420 group (1078.75, 568.87, 70.30 and 146.37 for WT, Delta, BA.1 and BA.2, respectively, in adults;  
421 1417.10, 751.08, 77.20 and 248.63 for WT, Delta, BA.1 and BA.2, respectively, in seniors) were  
422 generally higher or equal to that in the 25 µg dose group (825.85, 576.59, 45.51 and 91.11 for WT,  
423 Delta, BA.1 and BA.2, respectively, in adults; 1088.26, 587.73, 52.71 and 141.88 for WT, Delta,  
424 BA.1 and BA.2, respectively, in seniors). Particularly for neutralizing antibody against Omicron  
425 BA.1 (P=0.0262) and Omicron BA.2 (P=0.0399) in the younger cohort, the 45 µg dose group  
426 displayed a significantly higher response (Fig. 4E, F, G, H). The vaccine could elicit relatively  
427 higher or generally balanced GMT in seniors (Fig. 4E, F, G, H), which demonstrated that this  
428 vaccine was efficient in seniors group. The seroconversion rate of antibodies 14 days after the  
429 second dose against each strain were balanced without significant distinction among senior  
430 subjects, between the 45 µg dose group (100.0%, 97.9%, 74.5% and 85.1 for WT, Delta, BA.1 and  
431 BA.2, respectively) and 25 µg dose group (100.0%, 100.0%, 81.3% and 93.8 for WT, Delta, BA.1  
432 and BA.2, respectively) (Supplementary Fig. 2 E, F, G, H). However, among the younger cohort,  
433 the seroconversion rate of BA.2 antibodies was remarkably higher in the 25 µg dose group than  
434 that in the 45 µg dose group (96.8% vs. 89.3%) (Supplementary Fig. 2H), and the seroconversion  
435 rate of WT (100.0% vs 99.0%), Delta (98.9% vs 98.1%), BA.1 (85.1.0% vs 89.3%) was generally  
436 balanced (Supplementary Fig. 2 E, F, G). There was no obvious decline in seroconversion rates of  
437 each strain from 90 days to 180 days after full immunization for both age cohorts in either the 45  
438 µg dose or 25 µg dose group. The slight increase in the seroconversion rate at certain time points  
439 might be attributed to changes in the number of participants or infection during the epidemic.  
440 In the phase 1 trial, at 14 days after the second dose, the GMT of WT neutralizing antibody was  
441 302.57 in the 45 µg dose group and 161.34 in the 25 µg dose group (Fig. 5A). The seroconversion  
442 rates of WT neutralizing antibody were 94.4% in the 45 µg dose group and 100.0% in the 25 µg  
443 dose group at 14 days after full immunization (Fig. 5B). There was no significant difference  
444 between the 25 µg dose group and the 45 µg dose group (P=0.4737). In the phase 2 trial, when



445 comparing between the adult cohort and senior cohort, the GMT of neutralizing antibody against  
446 WT 14 days after full immunization were 270.81 vs. 438.68 in the 45  $\mu$ g dose group, 352.83 vs.  
447 249.71 in the 25  $\mu$ g dose group, and 9.44 vs. 6.51 in the placebo group, respectively (Fig. 5C). In  
448 all age groups, neutralizing antibody levels were significantly higher in both the 45  $\mu$ g dose group  
449 and 25  $\mu$ g dose group compared with the placebo group ( $P < 0.0001$ ). Among adults, there was no  
450 significant difference between the 45  $\mu$ g dose group and 25  $\mu$ g dose group ( $P = 0.0809$ ). However,  
451 in the senior group, the neutralizing antibody titer in the 45  $\mu$ g dose group was significantly higher  
452 than that in the 25  $\mu$ g dose group ( $P = 0.0264$ ). At 14 days post second dose, the seroconversion  
453 rates among adult subjects were similar to that among senior subjects. The seroconversion rates  
454 were 97.1% vs. 97.9% in the 45  $\mu$ g dose group, 97.9% vs. 96.9% in the 25  $\mu$ g dose group, and  
455 21.2% vs. 10.0% in the placebo group (Fig. 5D). Among the age groups, there was a significant  
456 difference in the seroconversion rates between the vaccine group and the placebo group  
457 ( $P < 0.0001$ ), while there was no significant difference in the seroconversion rates between the 45  
458  $\mu$ g dose group and the 25  $\mu$ g dose group ( $P = 0.8442$ ).

## 459 **Discussion**

460 In both phase 1 and phase 2 trials, we observed that two-dose SW-BIC-213 with the 25 or 45  $\mu$ g  
461 doses was well tolerated, with all adverse reactions mainly being transient and could resolved  
462 spontaneously. Notably, no of vaccination-related SAE or adverse events of special interest, like  
463 ADE/VED, was noticed since the first dose. Adverse reactions in both phase 1 and phase 2 were  
464 primarily manifested as local solicited reactions, with the most common symptoms being injection-  
465 site pain. Importantly, the frequency of solicited systemic adverse reactions events between the  
466 vaccine and placebo groups was similar in phase 2. Only a few adults in both the vaccine and  
467 placebo groups experienced grade  $\geq 3$  adverse reactions in phase 2, notably fever. Other reactions  
468 were generally limited to Grade 1-2. Overall, SW-BIC-213 showed favorable safe profile with  
469 generally mild or moderate reactogenicity, comparable to two well-known mRNA vaccine,  
470 mRNA-1273<sup>18,19</sup> and BNT162b2<sup>20,21</sup>.  
471 Humoral responses have been considered as immune correlates of protection against SARS-CoV-  
472 2<sup>22</sup>. SW-BIC-213 exhibited high immunogenicity and induced robust humoral responses rapidly.  
473 Specifically, for S-protein IgG antibody, one dose of vaccination could induce comparable

474 seroconversion rate to that achieved after full immunization, which was roughly equal between 45  
475  $\mu\text{g}$  dose and 25  $\mu\text{g}$  dose group. In contrast, the seroconversion rate of pseudo-virus neutralizing  
476 antibody showed an increasing tendency with the progression of the vaccination regimen, reaching  
477 higher levels after completing full immunization, regardless of dosage. As for GMT analysis, both  
478 IgG and neutralizing antibodies were induced in a dose-dependent manner. Furthermore, as new  
479 variants continue to emerge and cause devastation, the neutralizing antibodies against multiple  
480 VOC strains were also evaluated. Our candidate was similar potent against Delta strain compared  
481 to WT strain with both high seroconversion rate (>97%) and GMT. Meanwhile, in line with  
482 previous results<sup>23-27</sup>, a remarkable reduction of neutralizing antibodies was found against the  
483 Omicron variants, though the seroconversion rate was high to approximate 80% and 96% for  
484 Omicron BA.1 and BA.2 respectively at 14 days post full vaccination. For participants aged 60  
485 years and older, especially with pre-existing respiratory or cardiovascular disease, COVID-19  
486 presents a remarkably high risk of severe disease and death<sup>28</sup>. Notably, in this study, the magnitude  
487 of humoral immunogenicity in the group aged above 60 years was comparable to that of in the  
488 group aged 18–60 years in the context of similar safety profile.

489 The long-term tolerability profile of SW-BIC-213 and persistence of the elicited immune  
490 responses were also investigated according to the study protocol. Indicated with phase 1 and phase  
491 2 trial result, seroconversion rate of WT neutralizing antibody, Delta neutralizing antibody and S-  
492 protein specific antibody could remain at a relatively high level when coming to 90 days and 180  
493 days after full immunization. Situation that seroconversion rate of Omicron BA.1 and Omicron  
494 BA.2 neutralizing antibody slightly increased from 90 days to 180 days after full immunization  
495 and situation that seroconversion rate of placebo group could reach 50% suggests that there might  
496 have been exposure to pathogens or infections during the course of trial and leading to increased  
497 antibody levels in individual subjects. Since there was large epidemic in Laos during the trial, this  
498 was likely to occur across the groups and did not affect the key conclusion of the comparison  
499 between groups. As SARS-CoV-2 continues to evolve and vaccination induced protective  
500 immunity declines, the world has been through many waves of COVID-19 pandemic, and many  
501 people have experienced breakthrough infections. Those who have been both vaccinated and  
502 infected with SARS-CoV-2 can produce much stronger immune response compared to those who  
503 have only been vaccinated or infected. Several studies suggest that hybrid immunity confers more  
504 effective cross-variant neutralization and more durable protection against new infections<sup>29-31</sup>. The

505 investigational vaccine demonstrated the ability to induce a substantial humoral immune response,  
506 characterized by an outstanding seroconversion rate and significant increases in neutralizing titer  
507 and S-protein specific antibody from baseline.

508 This study also had several limitations. Firstly, data interpretation was based on a relatively small  
509 sample size and more data from ongoing phase 3 trials will provide further data to comprehensively  
510 evaluate the safety and efficacy of SW-BIC-213 as a booster shot in the heterologous boost  
511 regimen. Secondly, the study populations were not ethnically diverse, with all participants were of  
512 Asian descent. Thirdly, the neutralizing potency against currently circulating VOCs Omicron  
513 BA.4/5 was not evaluated in the present due to the constantly shifting of variants of concern, which  
514 will be addressed in the ongoing phase 3 trials.

515 In conclusion, COVID-19 mRNA vaccine SW-BIC-213 manifests a favorable safety profile and  
516 was highly immunogenic in all eligible subjects aged  $\geq 18$  years of both phase 1 and phase 2 trials,  
517 suggesting potential for further investigation as a means of controlling and preventing COVID-19.  
518 However, considering that COVID-19 vaccines have been widely used worldwide as primary  
519 series, the majority of targeted population may already have some extent of protection, thus a  
520 specific dosage of 25  $\mu\text{g}$  would be set for the booster study. Moreover, with the rising number of  
521 breakthrough infections of SARS-CoV-2 in previously immunized individuals, there is increasing  
522 concern for the need of a booster vaccine dose to combat waning antibody levels and new variants.  
523 As a result, an ongoing phase 3 study in Laos is further evaluating SW-BIC-213 as a booster  
524 vaccination against the Omicron variant and other emerging VOC in healthy individuals aged 18  
525 years and above, who have already completed the 2-dose series with COVID-19 inactivated  
526 vaccines.

527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539

540 **Author contributions**


541 M Mayxay is the principal investigator of this trial. D D, C P, B Yu, J-Y Wu and Y-Z  
542 Wang participated in designing the trial and study protocol. R-J Pei and P-P Liu  
543 contributed to laboratory testing. P Han and M-Y Shen contributed to develop and  
544 manufacture SW-BIC-213. Y-J Chen contributed to manuscript writing. S-K Lan, Y Li  
545 and B Luo participated in the site work, including the recruitment, participants' visits and  
546 data collection. J-X Li, H-F Shen, W-X Guan and H-W Li contributed to the critical  
547 review and revising of the manuscript. D-W Lv, L-R Jin, F-F Zhao and C-C Xu  
548 contributed to verify the data. All authors reviewed and approved the final version of the  
549 manuscript.

550 **Competing Interest Declaration**


551 The authors declare no competing interests.  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576

577 **Figure legends**

A Phase 1



B Phase 2



578

579 **Figure 1 Screening and Randomization of the Participants.**

580 The screening and Randomization profile of phase 1 (A) and Phase 2 (B) trial.

581

582

583

584


585

586 **Table 1. Baseline demographic characteristics of participants in phase 1 and phase 2 trials**



	Phase 1 trial (n=40)			Phase 2 trial (n=479)			
	25 µg (n=20)	45 µg (n=20)	P-value	Placebo (n=96)	25 µg (n=191)	45 µg (n=192)	P-value
<b>Age (years)</b>							
Mean (SD)	31.3 (10.3)	30.2 (10.0)	0.7337 <sup>[1]</sup>	46.3 (17.2)	47.5 (16.7)	47.3 (17.2)	0.8439 <sup>[3]</sup>
Median	28.5	27.0		46.5	49.0	48.0	
Q1, Q3	23.0, 38.0	23.0, 36.5		32.0, 60.0	32.0, 60.1	33.0, 60.5	
<b>Sex</b>							
Male	16 (80.0%)	15 (75.0%)	1.0000 <sup>[2]</sup>	62 (64.6)	92 (48.2%)	108 (56.3%)	0.0265 <sup>[4]</sup>
Female	4 (20.0%)	5 (25.0%)		34 (35.4)	99 (51.8%)	84 (43.8%)	
<b>Race</b>							
Asian	20 (100.0%)	20 (100.0%)	1.0000 <sup>[2]</sup>	96 (100.0%)	191 (100.0%)	192 (100.0%)	1.0000 <sup>[2]</sup>
<b>BMI (kg/m<sup>2</sup>)</b>							
Mean (SD)	21.510 (2.337)	23.175 (3.098)	0.0624 <sup>[1]</sup>	21.452 (3.370)	21.748 (3.475)	21.283 (3.345)	0.4040 <sup>[3]</sup>
Median	21.719	22.342		21.076	21.406	20.953	
Q1, Q3	20.1, 23.7	21.5, 23.8		19.1, 23.5	19.5, 23.6	19.2, 23.2	

587 Data are mean (SD), media, or n (%). p values are calculated with <sup>[1]</sup>t- test, <sup>[2]</sup>Fisher's exact test,  
 588 <sup>[3]</sup>ANOVA or <sup>[4]</sup>Chi-square test. BMI=body-mass index

A



B






590 **Figure 2 Vaccination-related adverse events and reactions in the phase 1 and phase 2 trials.**

591 A. Severity of Solicited Adverse Reactions in phase 1 trial.

592 B. Severity of Solicited Adverse Reactions in phase 2 trial, participants were divided into two  
593 age groups, 18-60 years old group (upper panel) and 60 years old above group (lower panel).

594 Severity of the adverse effects were classified according to the NIH guidelines. The Chi-square  
595 test was used to assess differences in the incidence of adverse effects among the specified groups.

596 The results of compared analysis among the three groups were expressed as no significant  
597 difference (ns,  $P > 0.5$ ), \* ( $p \leq 0.05$ ), \*\* ( $p \leq 0.01$ ), \*\*\* ( $p \leq 0.001$ ), \*\*\*\* ( $p \leq 0.0001$ ).



599 **Figure 3 SW-BIC-213 induced Spike protein binding antibodies in phase 1 and phase 2 trials.**

600 A. Geometric mean SARS-CoV-2 spike protein binding antibodies titers determined by ELISA  
601 at the indicated time points (day) post vaccination in phase 1 trial.

602 B. Seroconversion rates at the indicated time points (day) post vaccination in phase 1 trial.


603 C. Geometric mean SARS-CoV-2 spike protein binding antibodies titers determined by ELISA  
604 at the indicated time points (day) post vaccination in phase 2 trial.

605 D. Seroconversion rates at the indicated time points (day) post vaccination in phase 2 trial.

606 Seroconversion is defined as Titer above or equal 20 in baseline-seronegative subjects or at least  
607 4-fold rise in baseline-seropositive subjects. Statistical analysis was conducted with t test to  
608 compare the log transformed GMTs of the indicated group. Chi-square test was used to analyze  
609 the difference of seroconversion rate of the indicated group. The results of compared analysis were  
610 expressed as no significant difference (ns,  $P>0.5$ ), \* ( $p\leq 0.05$ ), \*\* ( $p\leq 0.01$ ), \*\*\* ( $p\leq 0.001$ ), \*\*\*\*  
611 ( $p\leq 0.0001$ ).

612

613



614

615

616 **Figure 4 SW-BIC-213 induced pseudo-virus neutralizing antibodies in phase 1 and phase 2**  
617 **trials.**

618 A. GMT of SARS-CoV-2 prototype strain pseudo-virus neutralizing antibody was determined at  
619 the indicated time points (day) in phase 1 trial.

620 B. GMT of SARS-CoV-2 delta strain pseudo-virus neutralizing antibody was determined at the  
621 indicated time points(day) in phase 1 trial.

622 C. GMT of SARS-CoV-2 omicron BA.1 strain pseudo-virus neutralizing antibody was  
623 determined at the indicated time points (day) in phase 1 trial.

624 D. GMT of SARS-CoV-2 omicron BA.2 strain pseudo-virus neutralizing antibody was  
625 determined at the indicated time points (day) in phase 1 trial.

626 E. GMT of SARS-CoV-2 prototype strain pseudo-virus neutralizing antibody was determined at  
627 the indicated time points (day) in phase 2 trial.

628 F. GMT of SARS-CoV-2 delta strain pseudo-virus neutralizing antibody was determined at the  
629 indicated time points(day) in phase 2 trial.

630 G. GMT of SARS-CoV-2 omicron BA.1 strain pseudo-virus neutralizing antibody was  
631 determined at the indicated time points (day) in phase 2 trial.

632 H. GMT of SARS-CoV-2 omicron BA.2 strain pseudo-virus neutralizing antibody was  
633 determined at the indicated time points (day) in phase 2 trial.

634 Statistical analysis was conducted with t test to compare the log transformed GMTs of the indicated  
635 group. The results of compared analysis were expressed as no significant difference (ns,  $P>0.5$ ), \*  
636 ( $p\leq 0.05$ ), \*\* ( $p\leq 0.01$ ), \*\*\* ( $p\leq 0.001$ ), \*\*\*\* ( $p\leq 0.0001$ ).

637

638

639

640

641

642


643

644


645

646


A




B



C



D



647

648

649

650

651

652

653

654

655

656

657

658

659 **Figure 5 SW-BIC-213 induced neutralizing antibodies in phase 1 and phase 2 trials.**

660 A. GMT of SARS-CoV-2 prototype virus neutralizing antibody determined by  
661 microneutralization assay in phase 1 trial.

662 B. The seroconversion rate of SARS-CoV-2 prototype virus neutralizing antibody in phase 1 trial.

663 C. GMT of SARS-CoV-2 prototype virus neutralizing antibody determined by  
664 microneutralization assay in phase 2 trial.

665 D. The seroconversion rate of SARS-CoV-2 prototype virus neutralizing antibody in phase 2 trial.

666 Seroconversion is defined as titers above or equal 4 in baseline-seronegative subjects or at least 4-  
667 fold rise in baseline-seropositive subjects in phase 1 trial. Seroconversion is defined as titers above  
668 or equal 10 in baseline-seronegative subjects or at least 4-fold rise in baseline-seropositive subjects  
669 in phase 2 trial (the diversity in seroconversion definition from that of phase 2 is attributed to the  
670 difference in detection institution and detection standard). Statistical analysis was conducted with  
671 t test to compare the log transformed GMTs of the indicated group. Chi-square test was used to  
672 analyze the difference of seroconversion rate of the indicated group. The results of compared  
673 analysis were expressed as no significant difference (ns,  $P>0.5$ ), \* ( $p\leq 0.05$ ), \*\* ( $p\leq 0.01$ ), \*\*\*  
674 ( $p\leq 0.001$ ), \*\*\*\* ( $p\leq 0.0001$ ).

675

676

677

678

679

680

681

682

683

684

685

686


687

688

689

690





691

692 **Extended Data Figure 1 SW-BIC-213 induced RBD binding antibodies in phase 1 trial.**

693 A. SARS-CoV-2 RBD protein binding antibody titer determined by ELISA.

694 B. The seroconversion rate of SARS-CoV-2 RBD protein binding antibody.

695 Seroconversion is defined as Titer above or equal 20 in baseline-seronegative subjects or at least

696 4-fold rise in baseline-seropositive subjects. Statistical analysis was conducted with t test to

697 compare the log transformed GMTs of the indicated group. Chi-square test was used to analyze

698 the difference of seroconversion rate of the indicated group. The results of compared analysis were

699 expressed as no significant difference (ns,  $P > 0.5$ ), \* ( $p \leq 0.05$ ), \*\* ( $p \leq 0.01$ ), \*\*\* ( $p \leq 0.001$ ), \*\*\*\*

700 ( $p \leq 0.0001$ ).

701

702

703

704


705

706

707

708

709



710  
711  
712  
713

714 **Extended Data Figure 2 Seroconversion rate of SW-BIC-213 induced pseudo-virus**  
715 **neutralizing antibodies in phase 1 and phase 2 trials.**

716 A. The seroconversion rate of SARS-CoV-2 prototype strain pseudo-virus neutralizing antibody  
717 at the indicated time points (day) in phase 1 trial.

718 B. The seroconversion rate of SARS-CoV-2 delta strain pseudo-virus neutralizing antibody at the  
719 indicated time points (day) in phase 1 trial.

720 C. The seroconversion rate of SARS-CoV-2 omicron BA.1 strain pseudo-virus neutralizing  
721 antibody at the indicated time points (day) in phase 1 trial.

722 D. The seroconversion rate of SARS-CoV-2 omicron BA.2 strain pseudo-virus neutralizing  
723 antibody at the indicated time points (day) in phase 1 trial.

724 E. The seroconversion rate of SARS-CoV-2 prototype strain pseudo-virus neutralizing antibody  
725 at the indicated time points (day) in phase 2 trial.

726 F. The seroconversion rate of SARS-CoV-2 delta strain pseudo-virus neutralizing antibody at the  
727 indicated time points (day) in phase 2 trial.

728 G. The seroconversion rate of SARS-CoV-2 omicron BA.1 strain pseudo-virus neutralizing  
729 antibody at the indicated time points (day) in phase 2 trial.

730 H. The seroconversion rate of SARS-CoV-2 omicron BA.2 strain pseudo-virus neutralizing  
731 antibody at the indicated time points (day) in phase 2 trial.

732 Seroconversion is defined as titers above or equal 10 in baseline-seronegative subjects or at least  
733 4-fold rise in baseline-seropositive subjects. Chi-square test was used to analyze the difference of  
734 seroconversion rate of the indicated group. The results of compared analysis among the three  
735 groups were expressed as no significant difference ns ( $P>0.5$ ), \* ( $p\leq 0.05$ ), \*\* ( $p\leq 0.01$ ), \*\*\* ( $p$   
736  $\leq 0.001$ ), \*\*\*\* ( $p\leq 0.0001$ ).

737

738

739

740

741

742

## 743 REFERENCES

- 744  
745 1 Cucinotta, D. & Vanelli, M. WHO Declares COVID-19 a Pandemic. *Acta bio-medica : Atenei*  
746 *Parmensis* **91**, 157-160, doi:10.23750/abm.v91i1.9397 (2020).  
747 2 <https://covid19.who.int/>.  
748 3 Jin, Y., Hou, C., Li, Y., Zheng, K. & Wang, C. mRNA Vaccine: How to Meet the Challenge of  
749 SARS-CoV-2. *Frontiers in immunology* **12**, 821538, doi:10.3389/fimmu.2021.821538  
750 (2021).  
751 4 [https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines)  
752 [vaccines](https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines).  
753 5 Angeli, F., Spanevello, A., Reboldi, G., Visca, D. & Verdecchia, P. SARS-CoV-2 vaccines:  
754 Lights and shadows. *European journal of internal medicine* **88**, 1-8,  
755 doi:10.1016/j.ejim.2021.04.019 (2021).  
756 6 Golob, J. L., Lugogo, N., Luring, A. S. & Lok, A. S. SARS-CoV-2 vaccines: a triumph of  
757 science and collaboration. *JCI insight* **6**, doi:10.1172/jci.insight.149187 (2021).  
758 7 Graña, C. *et al.* Efficacy and safety of COVID-19 vaccines. *The Cochrane database of*  
759 *systematic reviews* **12**, Cd015477, doi:10.1002/14651858.Cd015477 (2022).  
760 8 Ura, T., Yamashita, A., Mizuki, N., Okuda, K. & Shimada, M. New vaccine production  
761 platforms used in developing SARS-CoV-2 vaccine candidates. *Vaccine* **39**, 197-201,  
762 doi:10.1016/j.vaccine.2020.11.054 (2021).  
763 9 Sharma, A., Ahmad Farouk, I. & Lal, S. K. COVID-19: A Review on the Novel Coronavirus  
764 Disease Evolution, Transmission, Detection, Control and Prevention. *Viruses* **13**,  
765 doi:10.3390/v13020202 (2021).  
766 10 Awadasseid, A., Wu, Y., Tanaka, Y. & Zhang, W. Current advances in the development of  
767 SARS-CoV-2 vaccines. *International journal of biological sciences* **17**, 8-19,  
768 doi:10.7150/ijbs.52569 (2021).  
769 11 Skowronski, D. M. & De Serres, G. Safety and Efficacy of the BNT162b2 mRNA Covid-19  
770 Vaccine. *The New England journal of medicine* **384**, 1576-1577,  
771 doi:10.1056/NEJMc2036242 (2021).  
772 12 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *The New*  
773 *England journal of medicine* **384**, 403-416, doi:10.1056/NEJMoa2035389 (2021).  
774 13 Gui, Y. Z. *et al.* Safety and immunogenicity of a modified COVID-19 mRNA vaccine, SW-  
775 BIC-213, as a heterologous booster in healthy adults: an open-labeled, two-centered and  
776 multi-arm randomised, phase 1 trial. *EBioMedicine* **91**, 104586,  
777 doi:10.1016/j.ebiom.2023.104586 (2023).  
778 14 Yang, R. *et al.* A core-shell structured COVID-19 mRNA vaccine with favorable  
779 biodistribution pattern and promising immunity. *Signal transduction and targeted*  
780 *therapy* **6**, 213, doi:10.1038/s41392-021-00634-z (2021).  
781 15 <https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables>.  
782 16 <https://www.nmpa.gov.cn/yaopin/ypgggtg/ypqgtgg/20191231111901460.html>.

- 783 17 [https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical)  
784 [grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical)  
785 [clinical](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical).
- 786 18 Jackson, L. A. *et al.* An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. *N Engl J*  
787 *Med* **383**, 1920-1931, doi:10.1056/NEJMoa2022483 (2020).
- 788 19 Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med*  
789 **384**, 403-416, doi:10.1056/NEJMoa2035389 (2021).
- 790 20 Walsh, E. E. *et al.* Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine  
791 Candidates. *N Engl J Med* **383**, 2439-2450, doi:10.1056/NEJMoa2027906 (2020).
- 792 21 Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J*  
793 *Med* **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
- 794 22 Dai, L. & Gao, G. F. Viral targets for vaccines against COVID-19. *Nat Rev Immunol* **21**, 73-  
795 82, doi:10.1038/s41577-020-00480-0 (2021).
- 796 23 Cameroni, E. *et al.* Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron  
797 antigenic shift. *Nature* **602**, 664-670, doi:10.1038/s41586-021-04386-2 (2022).
- 798 24 <SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent  
799 Persons.pdf>.
- 800 25 Liu, L. *et al.* Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2.  
801 *Nature* **602**, 676-681, doi:10.1038/s41586-021-04388-0 (2022).
- 802 26 <Plasma Neutralization of the SARS-CoV-2 Omicron Variant.pdf>.
- 803 27 Carreno, J. M. *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2  
804 Omicron. *Nature* **602**, 682-688, doi:10.1038/s41586-022-04399-5 (2022).
- 805 28 Weiss, P. & Murdoch, D. R. Clinical course and mortality risk of severe COVID-19. *The*  
806 *Lancet* **395**, 1014-1015, doi:10.1016/s0140-6736(20)30633-4 (2020).
- 807 29 Suryawanshi, R. & Ott, M. SARS-CoV-2 hybrid immunity: silver bullet or silver lining?  
808 *Nature reviews. Immunology* **22**, 591-592, doi:10.1038/s41577-022-00771-8 (2022).
- 809 30 Wang, Z. *et al.* Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after  
810 infection. *Nature* **595**, 426-431, doi:10.1038/s41586-021-03696-9 (2021).
- 811 31 Suryawanshi, R. K. *et al.* Limited cross-variant immunity from SARS-CoV-2 Omicron  
812 without vaccination. *Nature* **607**, 351-355, doi:10.1038/s41586-022-04865-0 (2022).
- 813